Discover investment opportunities in Undervalued Pharma Stocks Today using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Undervalued Pharma Stocks Today using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Undervalued Pharma Stocks Today using our Smart AI Filter.
10 stocks found for "Undervalued Pharma Stocks Today"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.60 | ±27.2% | 15.6 | 3.47% | |||
0.22 | ±27.3% | 15.0 | 2.83% | |||
0.74 | ±35.0% | 3.5 | 5.20% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.35 | ±28.9% | 6.7 | 5.29% | |||
0.45 | ±25.0% | 14.4 | 3.19% | |||
0.59 | ±31.6% | 34.5 | 0.77% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
1.03 | ±49.2% | 6.1 | 2.00% | |||
0.33 | ±27.9% | 8.6 | 4.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How can I identify if a pharmaceutical stock like VTRS or TEVA is undervalued?
A: Investors often look at the price-to-earnings (P/E) ratio to identify undervaluation. A lower P/E compared to industry peers may suggest undervaluation. It's important to analyze factors like patent cliffs, pipeline strength, and market conditions for a complete assessment.
Q: What are common growth indicators for biotech companies like VRTX or LLY?
A: Growth indicators include revenue growth rates, R&D spending, and drug pipeline developments. Companies like VRTX with breakthrough treatments or LLY with expanding indications for existing drugs may show strong growth potential.
Q: Why might income-focused investors consider stocks like ABBV or AMGN?
A: Some investors consider these stocks for their consistent dividend payments. ABBV offers a historically high dividend yield, while AMGN has a track record of regular dividend increases, appealing to income-focused investors.
Q: How do regulatory approvals affect a stock like PFE?
A: Regulatory approvals can significantly impact stock value, indicating the potential for revenue growth. For PFE, approvals of new drugs or indications can lead to increased market share and positively influence stock performance.
Q: What role does innovation play in the valuation of a company like GILD?
A: Innovation is crucial, especially in biotech. GILD's valuation depends on the development of new therapies and treatments tackling unmet medical needs, which can drive future revenue and influence investor perception.
Q: Are there any economic cycle considerations for pharmaceutical stocks like MRK?
A: Pharmaceuticals are considered defensive because demand remains stable during economic downturns. MRK may appeal to investors seeking stability, as healthcare needs persist regardless of economic conditions.
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read morePresident Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Read more